Latest Content

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

In a cross-sectional study of US hospitals, patient financial assistance and billing policy documents averaged 10th-grade readability scores, with variation significantly associated with several attributes.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

A Brown University–led review synthesizes GDMT, comorbidity management, and emerging therapies into a hospital-based framework for HFpEF.

Adults treated with insulin showed sustained A1C improvements and fewer acute care visits among patients whose CGM was initiated in primary care compared with similar patients who did not initiate CGM.